摘要：SummaryAsperuloside (ASP) is an iridoid glycoside that is extracted fromEucommialeaves.Eucommiais used in traditional Chinese medicine and has a long history of benefits on health and longevity. Here, we investigated the impact of ASP on obesity-related metabolic disorders and show that ASP reduces body weight gain, glucose intolerance, and insulin resistance effectively in mice fed with a high-fat diet (HFD). Intestinal dysbiosis is closely linked with metabolic disorders. Our data indicate that ASP achieves these benefits on metabolic homeostasis by reversing HFD-induced gut dysbiosis and by changing gut-derived secondary metabolites and metabolic signaling. Our results indicate that ASP may be used to regulate gut microbiota for the treatment of obesity and type 2 diabetes.Graphical AbstractDisplay OmittedHighlights•Asperuloside (ASP) treatment improved obesity-related metabolic dysfunction in miceASP administration changed intestinal metabolite via modulation of gut microbiotaASP administration increasedParabacteroidesandAkkermansiain intestineGut microbiota-derived metabolite improves adipose tissue and intestinal dysfunctionHuman Metabolism; Microbiome
